Kite presents CAR T-cell therapy portfolio at ICML 2025

Kite, a Gilead Company, will share eight abstracts, including two oral presentations, across its portfolio of Chimeric Antigen Receptor (CAR) T-cell therapies Yescarta^® (axicabtagene ciloleucel) and Tecartus^® (brexucabtagene autoleucel) and next-generation pipeline, at the International Conference on Malignant Lymphoma (ICML) Congress on 17-21 June 2025 in Lugano, Switzerland.

T-cell therapy data includes real-world outcomes from the largest cohort of patients treated with axicabtagene ciloleucel for Richter Transformation to Large B-cell Lymphoma (RT-LBCL) from the Center for International Blood and Marrow Transplant Research (CIBMTR), which shows promising effectiveness at a median follow-up of 26 months, with a median duration of response of 19 months, in this patient population with high unmet medical need.

T-cell therapy deemed safe for cancer treatment

The analysis shows a comparable safety profile to that observed in other LBCL studies.¹ Findings from the Phase 1 KITE-363 study, which investigates the potential next-generation CAR T-cell therapy for relapsed/refractory (R/R) B-cell lymphoma, will also be presented, demonstrating the tolerable safety profile of the investigational therapy.²

“Kite is pleased to once again attend ICML to present our latest advancements in haematological cancer treatment and build on our commitment to create a strong real-world evidence base for CAR T-cell therapy,” said Dan Tovar, Head of Medical Affairs Cell Therapy, Australia, Canada and Europe (ACE) region.

“We look forward to discussing the potential of our CAR T-cell therapy portfolio and our innovative pipeline to address the unmet need in difficult-to-treat blood cancers.”

References

1. Winter, et al. Real-World Outcomes of Axicabtagene Ciloleucel (AxiCel) for the Treatment of Richter Transformation to Large B-Cell Lymphoma (RT-LBCL). Abstract #143 presented at the 2025 International Conference on Malignant Lymphoma (ICML).
2. Dahiya, et al. A Phase 1 Study of KITE-363 anti-CD19/CD20 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients (pts) with Relapsed/Refractory (R/R) B-cell Lymphoma (BCL). Abstract #103 presented at the 2025 International Conference on Malignant Lymphoma (ICML).